Under its open Investigational New Drug Application with the U.S. FDA, @Pharnext is on track and expects to begin First-Patient-First-Dose in its clinical Pivotal Phase III Trial entitled PREMIER before March 31 in the U.S. Read more: https://t.co/hiuf0isl7T